{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:37:18Z","timestamp":1787020638921,"version":"build-2736575974"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Need Oriented Basic Research Project of Inner Mongolia Academy of Medical Sciences","award":["No. 2023GLLH0229"],"award-info":[{"award-number":["No. 2023GLLH0229"]}]},{"name":"Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes","award":["No.JYY2023-14"],"award-info":[{"award-number":["No.JYY2023-14"]}]},{"name":"Beijing Municipal Administration of Hospital Incubating Program","award":["No. PX2023059"],"award-info":[{"award-number":["No. PX2023059"]}]},{"name":"The Research Project of Inner Mongolia Medical University Affiliated Hospital","award":["2023NYFYLHZD007"],"award-info":[{"award-number":["2023NYFYLHZD007"]}]},{"name":"The Capability Program of Beijing Tuberculosis & Thoracic Tumor Research Institute","award":["nlts2024-16"],"award-info":[{"award-number":["nlts2024-16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06448-9","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:27:26Z","timestamp":1744802846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Application of EGFR-TKIs in brain tumors, a breakthrough in future?"],"prefix":"10.1186","volume":"23","author":[{"given":"Shiying","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilan","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"6448_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-3-031-23705-8_10","volume":"1405","author":"L Albano","year":"2023","unstructured":"Albano L, Losa M, Barzaghi LR, et al. Benign and malignant tumors of the pituitary gland. Adv Exp Med Biol. 2023;1405:281\u201397.","journal-title":"Adv Exp Med Biol"},{"key":"6448_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jocn.2018.12.022","volume":"62","author":"SW Cutfield","year":"2019","unstructured":"Cutfield SW, Wickremesekera AC, Mantamadiotis T, et al. Tumour stem cells in Schwannoma: A review. J Clin Neurosci. 2019;62:21\u20136.","journal-title":"J Clin Neurosci"},{"key":"6448_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023;9:29.","journal-title":"Nat Rev Dis Primers"},{"key":"6448_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"6448_CR5","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016\u20132020. Neuro Oncol. 2023;25:iv1\u201399.","journal-title":"Neuro Oncol"},{"key":"6448_CR6","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.4103\/2152-7806.111296","volume":"4","author":"KJ Stelzer","year":"2013","unstructured":"Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int. 2013;4:S192\u2013202.","journal-title":"Surg Neurol Int"},{"key":"6448_CR7","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.3747\/co.25.3733","volume":"25","author":"SM-B Abdallah","year":"2018","unstructured":"Abdallah SM-B, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol. 2018;25:S103\u201314.","journal-title":"Curr Oncol"},{"key":"6448_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10585-024-10271-9","volume":"41","author":"E Aleksandrovic","year":"2024","unstructured":"Aleksandrovic E, Zhang S, Yu D. From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities. Clin Exp Metastasis. 2024;41:187\u201398.","journal-title":"Clin Exp Metastasis"},{"key":"6448_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.2009.24.6314","volume":"28","author":"O Graesslin","year":"2010","unstructured":"Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol. 2010;28:2032\u20137.","journal-title":"J Clin Oncol"},{"key":"6448_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-030-30651-9_8","volume":"1202","author":"M Nakada","year":"2020","unstructured":"Nakada M, Kita D, Teng L, et al. Receptor tyrosine kinases: principles and functions in glioma invasion. Adv Exp Med Biol. 2020;1202:151\u201378.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"6448_CR11","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.3390\/cancers13092114","volume":"13","author":"V Intern\u00f2","year":"2021","unstructured":"Intern\u00f2 V, De Santis P, Stucci LS, et al. Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: an overview. Cancers (Basel). 2021;13(9):2114.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6448_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/cancers13040900","volume":"13","author":"S M\u00fcller","year":"2021","unstructured":"M\u00fcller S, K\u00f6hler F, Hendricks A, et al. Brain metastases from colorectal cancer: A systematic review of the literature and Meta-Analysis to Establish a guideline for daily treatment. Cancers (Basel). 2021;13(4):900.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"6448_CR13","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"MJ Wieduwilt","year":"2008","unstructured":"Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566\u201384.","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"6448_CR14","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.3390\/cancers13112748","volume":"13","author":"ML Uribe","year":"2021","unstructured":"Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers (Basel). 2021;13(11):2748.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6448_CR15","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1074\/jbc.272.5.2927","volume":"272","author":"HS Huang","year":"1997","unstructured":"Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272(5):2927\u201335.","journal-title":"J Biol Chem"},{"issue":"7","key":"6448_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/neuonc\/nov319","volume":"18","author":"AH Thorne","year":"2016","unstructured":"Thorne AH, Zanca C, Furnari F. Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol. 2016;18(7):914\u20138.","journal-title":"Neuro Oncol"},{"issue":"3","key":"6448_CR17","doi-asserted-by":"publisher","first-page":"105763","DOI":"10.1016\/j.jbc.2024.105763","volume":"300","author":"JL Macdonald-Obermann","year":"2024","unstructured":"Macdonald-Obermann JL, Pike LJ. Extracellular domain mutations of the EGF receptor differentially modulate high-affinity and low-affinity responses to EGF receptor ligands. J Biol Chem. 2024;300(3):105763.","journal-title":"J Biol Chem"},{"issue":"4","key":"6448_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/or.2024.8798","volume":"52","author":"NT Cini","year":"2024","unstructured":"Cini NT, Pennisi M, Genc S, et al. Glioma lateralization: focus on the anatomical localization and the distribution of molecular alterations (Review). Oncol Rep. 2024;52(4):139.","journal-title":"Oncol Rep"},{"issue":"1","key":"6448_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3892\/ol.2017.6221","volume":"14","author":"H Xu","year":"2017","unstructured":"Xu H, Zong H, Ma C, et al. Epidermal growth factor receptor in glioblastoma. Oncol Lett. 2017;14(1):512\u20136.","journal-title":"Oncol Lett"},{"issue":"4","key":"6448_CR20","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/ijms25042316","volume":"25","author":"S Ezzati","year":"2024","unstructured":"Ezzati S, Salib S, Balasubramaniam M, et al. Epidermal growth factor receptor inhibitors in glioblastoma: current status and future possibilities. Int J Mol Sci. 2024;25(4):2316.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"6448_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/cells8080863","volume":"8","author":"AS Silantyev","year":"2019","unstructured":"Silantyev AS, Falzone L, Libra M, et al. Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics. Cells. 2019;8(8):863.","journal-title":"Cells"},{"key":"6448_CR22","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1073\/pnas.89.7.2965","volume":"89","author":"AJ Wong","year":"1992","unstructured":"Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992;89:2965\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6448_CR23","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/jnci\/93.16.1246","volume":"93","author":"JS Smith","year":"2001","unstructured":"Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic Astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246\u201356.","journal-title":"J Natl Cancer Inst"},{"key":"6448_CR24","first-page":"4307","volume":"62","author":"A Chakravarti","year":"2002","unstructured":"Chakravarti A, Chakladar A, Delaney MA, et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002;62:4307\u201315.","journal-title":"Cancer Res"},{"key":"6448_CR25","first-page":"6962","volume":"63","author":"N Shinojima","year":"2003","unstructured":"Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962\u201370.","journal-title":"Cancer Res"},{"key":"6448_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","volume":"96","author":"F Hsu","year":"2016","unstructured":"Hsu F, De Caluwe A, Anderson D, et al. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016;96:101\u20137.","journal-title":"Lung Cancer"},{"key":"6448_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2022","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, et al. Worldwide prevalence of epidermal growth factor receptor mutations in Non-Small cell lung cancer: A Meta-Analysis. Mol Diagn Ther. 2022;26:7\u201318.","journal-title":"Mol Diagn Ther"},{"key":"6448_CR28","doi-asserted-by":"publisher","first-page":"912505","DOI":"10.3389\/fonc.2022.912505","volume":"12","author":"W Zhao","year":"2022","unstructured":"Zhao W, Zhou W, Rong L, et al. Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer. Front Oncol. 2022;12:912505.","journal-title":"Front Oncol"},{"key":"6448_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/modpathol.3800830","volume":"20","author":"J Gaedcke","year":"2007","unstructured":"Gaedcke J, Traub F, Milde S, et al. Predominance of the basal type and HER-2\/neu type in brain metastasis from breast cancer. Mod Pathol. 2007;20:864\u201370.","journal-title":"Mod Pathol"},{"key":"6448_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2022.12.019","volume":"181","author":"P-C Chen","year":"2023","unstructured":"Chen P-C, Yeh Y-M, Chu C-T, et al. HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study. Eur J Cancer. 2023;181:62\u20139.","journal-title":"Eur J Cancer"},{"issue":"4","key":"6448_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/JCMA.0000000000000703","volume":"85","author":"CY Liu","year":"2022","unstructured":"Liu CY, Lin HF, Lai WY, et al. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers. J Chin Med Assoc. 2022;85(4):409\u201313.","journal-title":"J Chin Med Assoc"},{"issue":"2","key":"6448_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7888\/juoeh.41.153","volume":"41","author":"K Yoneda","year":"2019","unstructured":"Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of Non-small cell lung cancer with EGFR-mutations. J UOEH. 2019;41(2):153\u201363.","journal-title":"J UOEH"},{"issue":"2","key":"6448_CR33","first-page":"100103","volume":"2","author":"X Du","year":"2021","unstructured":"Du X, Yang B, An Q, et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innov (Camb). 2021;2(2):100103.","journal-title":"Innov (Camb)"},{"issue":"8","key":"6448_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ctrv.2014.06.010","volume":"40","author":"S Peters","year":"2014","unstructured":"Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014;40(8):917\u201326.","journal-title":"Cancer Treat Rev"},{"key":"6448_CR35","doi-asserted-by":"publisher","first-page":"103305","DOI":"10.1016\/j.critrevonc.2021.103305","volume":"160","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Cheng B, Chen Z, et al. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2021;160:103305.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"6448_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, et al. Preclinical comparison of the Blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27(1):189\u2013201.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 3","key":"6448_CR37","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","volume":"8","author":"NM Andrews Wright","year":"2019","unstructured":"Andrews Wright NM, Goss GD. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 3):S247\u201364.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"6448_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14656566.2022.2050213","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Wu L. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Expert Opin Pharmacother. 2022;23(6):647\u201352.","journal-title":"Expert Opin Pharmacother"},{"issue":"Supplement","key":"6448_CR39","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.4103\/ijc.IJC_449_19","volume":"56","author":"DC Doval","year":"2019","unstructured":"Doval DC, Desai CJ, Sahoo TP. Molecularly targeted therapies in non-small cell lung cancer: the evolving role of tyrosine kinase inhibitors. Indian J Cancer. 2019;56(Supplement):S23\u201330.","journal-title":"Indian J Cancer"},{"key":"6448_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","volume":"22","author":"JN Rich","year":"2004","unstructured":"Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133\u201342.","journal-title":"J Clin Oncol"},{"key":"6448_CR41","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/sj.bjc.6603669","volume":"96","author":"E Franceschi","year":"2007","unstructured":"Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by gruppo Italiano cooperativo Di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96:1047\u201351.","journal-title":"Br J Cancer"},{"key":"6448_CR42","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JWT, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130\u201340.","journal-title":"Clin Cancer Res"},{"key":"6448_CR43","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1074\/jbc.M807111200","volume":"284","author":"F Griffero","year":"2009","unstructured":"Griffero F, Daga A, Marubbi D, et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem. 2009;284:7138\u201348.","journal-title":"J Biol Chem"},{"key":"6448_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41401-020-0418-2","volume":"42","author":"C Chen","year":"2021","unstructured":"Chen C, Cheng C-D, Wu H, et al. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. Acta Pharmacol Sin. 2021;42:108\u201314.","journal-title":"Acta Pharmacol Sin"},{"key":"6448_CR45","doi-asserted-by":"publisher","first-page":"572904","DOI":"10.3389\/fonc.2020.572904","volume":"10","author":"Q Xia","year":"2020","unstructured":"Xia Q, Xu M, Zhang P, et al. Therapeutic potential of autophagy in glioblastoma treatment with phosphoinositide 3-Kinase\/Protein kinase B\/Mammalian target of Rapamycin signaling pathway inhibitors. Front Oncol. 2020;10:572904.","journal-title":"Front Oncol"},{"key":"6448_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00063030-200923010-00003","volume":"23","author":"RW Mercer","year":"2009","unstructured":"Mercer RW, Tyler MA, Ulasov IV, et al. Targeted therapies for malignant glioma: progress and potential. BioDrugs. 2009;23:25\u201335.","journal-title":"BioDrugs"},{"key":"6448_CR47","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1158\/1078-0432.CCR-07-4923","volume":"14","author":"H-W Lo","year":"2008","unstructured":"Lo H-W, Cao X, Zhu H, et al. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res. 2008;14:6042\u201354.","journal-title":"Clin Cancer Res"},{"key":"6448_CR48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4161\/cc.27518","volume":"13","author":"B Jutten","year":"2014","unstructured":"Jutten B, Rouschop KMA. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle. 2014;13:42\u201351.","journal-title":"Cell Cycle"},{"key":"6448_CR49","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1158\/1535-7163.MCT-09-0947","volume":"9","author":"F Yang","year":"2010","unstructured":"Yang F, Brown C, Buettner R, et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther. 2010;9:953\u201362.","journal-title":"Mol Cancer Ther"},{"key":"6448_CR50","first-page":"vdaa020","volume":"2","author":"KV Jensen","year":"2020","unstructured":"Jensen KV, Hao X, Aman A, et al. EGFR Blockade in GBM brain tumor stem cells synergizes with JAK2\/STAT3 pathway Inhibition to abrogate compensatory mechanisms in vitro and in vivo. Neurooncol Adv. 2020;2:vdaa020.","journal-title":"Neurooncol Adv"},{"issue":"8","key":"6448_CR51","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/cr.2014.89","volume":"24","author":"Y Wang","year":"2014","unstructured":"Wang Y, Gao J, Guo X, et al. Regulation of EGFR nanocluster formation by ionic protein-lipid interaction. Cell Res. 2014;24(8):959\u201376.","journal-title":"Cell Res"},{"issue":"4","key":"6448_CR52","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/jid.2009.415","volume":"130","author":"D Calay","year":"2010","unstructured":"Calay D, Vind-Kezunovic D, Frankart A, et al. Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J Invest Dermatol. 2010;130(4):1136\u201345.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"6448_CR53","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/sj.jid.5700168","volume":"126","author":"S Lambert","year":"2006","unstructured":"Lambert S, Vind-Kezunovic D, Karvinen S, et al. Ligand independent activation of the EGFR by lipid raft disruption. J Invest Dermatol. 2006;126(5):954\u201362.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"6448_CR54","doi-asserted-by":"publisher","first-page":"e10138","DOI":"10.1002\/btm2.10138","volume":"4","author":"CS Kim","year":"2019","unstructured":"Kim CS, Yang X, Jacobsen S, et al. Leader cell PLC\u03b31 activation during keratinocyte collective migration is induced by EGFR localization and clustering. Bioeng Transl Med. 2019;4(3):e10138.","journal-title":"Bioeng Transl Med"},{"key":"6448_CR55","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jnutbio.2015.09.018","volume":"27","author":"OA Alawin","year":"2016","unstructured":"Alawin OA, Ahmed RA, Ibrahim BA, et al. Antiproliferative effects of \u03b3-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells. J Nutr Biochem. 2016;27:266\u201377.","journal-title":"J Nutr Biochem"},{"issue":"4","key":"6448_CR56","first-page":"4423","volume":"15","author":"S Kishi","year":"2018","unstructured":"Kishi S, Fujiwara-Tani R, Luo Y, et al. Pro-metastatic signaling of the trans fatty acid Elaidic acid is associated with lipid rafts. Oncol Lett. 2018;15(4):4423\u20136.","journal-title":"Oncol Lett"},{"key":"6448_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.actbio.2019.02.026","volume":"88","author":"S Yamamoto","year":"2019","unstructured":"Yamamoto S, Iwamaru Y, Shimizu Y, et al. Epidermal growth factor-nanoparticle conjugates change the activity from anti-apoptotic to pro-apoptotic at membrane rafts. Acta Biomater. 2019;88:383\u201391.","journal-title":"Acta Biomater"},{"key":"6448_CR58","doi-asserted-by":"publisher","first-page":"188996","DOI":"10.1016\/j.bbcan.2023.188996","volume":"1878","author":"M Ge","year":"2023","unstructured":"Ge M, Zhu Y, Wei M, et al. Improving the efficacy of anti-EGFR drugs in GBM: where we are going? Biochim Biophys Acta Rev Cancer. 2023;1878:188996.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"6448_CR59","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jnci\/dji161","volume":"97","author":"DA Haas-Kogan","year":"2005","unstructured":"Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B\/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"6448_CR60","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s13046-021-02173-5","volume":"40","author":"R-Y Fan","year":"2021","unstructured":"Fan R-Y, Wu J-Q, Liu Y-Y, et al. Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis. J Exp Clin Cancer Res. 2021;40:371.","journal-title":"J Exp Clin Cancer Res"},{"key":"6448_CR61","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa051918","volume":"353","author":"IK Mellinghoff","year":"2005","unstructured":"Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012\u201324.","journal-title":"N Engl J Med"},{"key":"6448_CR62","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/neuonc\/nox191","volume":"20","author":"E Eskilsson","year":"2018","unstructured":"Eskilsson E, R\u00f8sland GV, Solecki G, et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2018;20:743\u201352.","journal-title":"Neuro Oncol"},{"key":"6448_CR63","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","volume":"2","author":"I Vivanco","year":"2012","unstructured":"Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2:458\u201371.","journal-title":"Cancer Discov"},{"key":"6448_CR64","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc3918","volume":"15","author":"FB Furnari","year":"2015","unstructured":"Furnari FB, Cloughesy TF, Cavenee WK, et al. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015;15:302\u201310.","journal-title":"Nat Rev Cancer"},{"key":"6448_CR65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1586\/14737140.3.5.595","volume":"3","author":"HB Newton","year":"2003","unstructured":"Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Rev Anticancer Ther. 2003;3:595\u2013614.","journal-title":"Expert Rev Anticancer Ther"},{"key":"6448_CR66","first-page":"141","volume":"40","author":"PL Penar","year":"1997","unstructured":"Penar PL, Khoshyomn S, Bhushan A, et al. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery. 1997;40:141\u201351.","journal-title":"Neurosurgery"},{"key":"6448_CR67","first-page":"3496","volume":"8","author":"AB Heimberger","year":"2002","unstructured":"Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to Blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res. 2002;8:3496\u2013502.","journal-title":"Clin Cancer Res"},{"key":"6448_CR68","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.yexcr.2011.03.015","volume":"317","author":"E Carrasco-Garc\u00eda","year":"2011","unstructured":"Carrasco-Garc\u00eda E, Saceda M, Grasso S, et al. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res. 2011;317:1476\u201389.","journal-title":"Exp Cell Res"},{"key":"6448_CR69","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-08-2042","volume":"15","author":"J-S Guillamo","year":"2009","unstructured":"Guillamo J-S, de Bo\u00fcard S, Valable S, et al. Molecular mechanisms underlying effects of epidermal growth factor receptor Inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res. 2009;15:3697\u2013704.","journal-title":"Clin Cancer Res"},{"key":"6448_CR70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1440-1681.12026","volume":"40","author":"W-J Xing","year":"2013","unstructured":"Xing W-J, Zou Y, Han Q-L, et al. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the Inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors. Clin Exp Pharmacol Physiol. 2013;40:13\u201321.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"6448_CR71","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11060-011-0632-3","volume":"105","author":"C-Y Chang","year":"2011","unstructured":"Chang C-Y, Shen C-C, Su H-L, et al. Gefitinib induces apoptosis in human glioma cells by targeting bad phosphorylation. J Neurooncol. 2011;105:507\u201322.","journal-title":"J Neurooncol"},{"key":"6448_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11060-015-1763-8","volume":"123","author":"MK Petri","year":"2015","unstructured":"Petri MK, Brobeil A, Planz J, et al. PTPIP51 levels in glioblastoma cells depend on Inhibition of the EGF-receptor. J Neurooncol. 2015;123:15\u201325.","journal-title":"J Neurooncol"},{"key":"6448_CR73","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.3390\/ijms22083934","volume":"22","author":"C-Y Chang","year":"2021","unstructured":"Chang C-Y, Pan P-H, Wu C-C, et al. Endoplasmic reticulum stress contributes to Gefitinib-Induced apoptosis in glioma. Int J Mol Sci. 2021;22:3934.","journal-title":"Int J Mol Sci"},{"key":"6448_CR74","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.yexcr.2014.05.011","volume":"327","author":"C-Y Chang","year":"2014","unstructured":"Chang C-Y, Kuan Y-H, Ou Y-C, et al. Autophagy contributes to gefitinib-induced glioma cell growth Inhibition. Exp Cell Res. 2014;327:102\u201312.","journal-title":"Exp Cell Res"},{"key":"6448_CR75","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/iub.1445","volume":"67","author":"C-Y Chang","year":"2015","unstructured":"Chang C-Y, Li J-R, Wu C-C, et al. Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy. IUBMB Life. 2015;67:869\u201379.","journal-title":"IUBMB Life"},{"key":"6448_CR76","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00018-020-03686-6","volume":"78","author":"A-F Blandin","year":"2021","unstructured":"Blandin A-F, Cruz Da Silva E, Mercier M-C, et al. Gefitinib induces EGFR and \u03915\u03b21 integrin co-endocytosis in glioblastoma cells. Cell Mol Life Sci. 2021;78:2949\u201362.","journal-title":"Cell Mol Life Sci"},{"key":"6448_CR77","first-page":"3335","volume":"62","author":"A Lal","year":"2002","unstructured":"Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62:3335\u20139.","journal-title":"Cancer Res"},{"key":"6448_CR78","first-page":"143","volume":"27","author":"A Bajetto","year":"2013","unstructured":"Bajetto A, Porcile C, Pattarozzi A, et al. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility. J Biol Regul Homeost Agents. 2013;27:143\u201354.","journal-title":"J Biol Regul Homeost Agents"},{"key":"6448_CR79","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s11596-011-0675-x","volume":"31","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Xing X, Zhan H, et al. EGFR inhibitor enhances cisplatin sensitivity of human glioma cells. J Huazhong Univ Sci Technolog Med Sci. 2011;31:773\u20138.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"6448_CR80","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","volume":"38","author":"R Vengoji","year":"2019","unstructured":"Vengoji R, Macha MA, Nimmakayala RK, et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res. 2019;38:266.","journal-title":"J Exp Clin Cancer Res"},{"key":"6448_CR81","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1038\/sj.onc.1205500","volume":"21","author":"JN Contessa","year":"2002","unstructured":"Contessa JN, Hampton J, Lammering G, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene. 2002;21:4032\u201341.","journal-title":"Oncogene"},{"key":"6448_CR82","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1038\/sj.onc.1201802","volume":"16","author":"S Carter","year":"1998","unstructured":"Carter S, Auer KL, Reardon DB, et al. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene. 1998;16:2787\u201396.","journal-title":"Oncogene"},{"key":"6448_CR83","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/1541-7786.MCR-08-0113","volume":"6","author":"H-C Lee","year":"2008","unstructured":"Lee H-C, An S, Lee H, et al. Activation of epidermal growth factor receptor and its downstream signaling pathway by nitric oxide in response to ionizing radiation. Mol Cancer Res. 2008;6:996\u20131002.","journal-title":"Mol Cancer Res"},{"key":"6448_CR84","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1101\/gad.1627008","volume":"22","author":"D Hambardzumyan","year":"2008","unstructured":"Hambardzumyan D, Becher OJ, Rosenblum MK, et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in Medulloblastoma in vivo. Genes Dev. 2008;22:436\u201348.","journal-title":"Genes Dev"},{"issue":"23","key":"6448_CR85","doi-asserted-by":"publisher","first-page":"7198","DOI":"10.1158\/0008-5472.CAN-11-1514","volume":"71","author":"J Acquaviva","year":"2011","unstructured":"Acquaviva J, Jun HJ, Lessard J, et al. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. Cancer Res. 2011;71(23):7198\u2013206.","journal-title":"Cancer Res"},{"issue":"1","key":"6448_CR86","first-page":"vdad066","volume":"5","author":"JE Conage-Pough","year":"2023","unstructured":"Conage-Pough JE, Stopka SA, Oh JH, et al. WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Neurooncol Adv. 2023;5(1):vdad066.","journal-title":"Neurooncol Adv"},{"issue":"22","key":"6448_CR87","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.18632\/oncotarget.27599","volume":"11","author":"G Chagoya","year":"2020","unstructured":"Chagoya G, Kwatra SG, Nanni CW, et al. Efficacy of osimertinib against EGFRvIII + glioblastoma. Oncotarget. 2020;11(22):2074\u201382.","journal-title":"Oncotarget"},{"issue":"12","key":"6448_CR88","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/neuonc\/noz127","volume":"21","author":"G Guo","year":"2019","unstructured":"Guo G, Gong K, Puliyappadamba VT, et al. Efficacy of EGFR plus TNF Inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro Oncol. 2019;21(12):1529\u201339.","journal-title":"Neuro Oncol"},{"key":"6448_CR89","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bjc.6602793","volume":"93","author":"MW Pedersen","year":"2005","unstructured":"Pedersen MW, Pedersen N, Ottesen LH, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005;93:915\u201323.","journal-title":"Br J Cancer"},{"key":"6448_CR90","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1073\/pnas.0510284103","volume":"103","author":"H Ji","year":"2006","unstructured":"Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006;103:7817\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"6448_CR91","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/cancers16051001","volume":"16","author":"FV Celeste","year":"2024","unstructured":"Celeste FV, Powers S. Induction of multiple alternative mitogenic signaling pathways accompanies the emergence of Drug-Tolerant cancer cells. Cancers (Basel). 2024;16(5):1001.","journal-title":"Cancers (Basel)"},{"key":"6448_CR92","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1126\/science.1142946","volume":"318","author":"JM Stommel","year":"2007","unstructured":"Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287\u201390.","journal-title":"Science"},{"key":"6448_CR93","first-page":"8930","volume":"63","author":"Q-W Fan","year":"2003","unstructured":"Fan Q-W, Specht KM, Zhang C, et al. Combinatorial efficacy achieved through two-point Blockade within a signaling pathway-a chemical genetic approach. Cancer Res. 2003;63:8930\u20138.","journal-title":"Cancer Res"},{"key":"6448_CR94","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, et al. Preclinical comparison of the Blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27:189\u2013201.","journal-title":"Clin Cancer Res"},{"key":"6448_CR95","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41420-023-01632-6","volume":"9","author":"L Hu","year":"2023","unstructured":"Hu L, Shi J, Shen D, et al. Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells. Cell Death Discov. 2023;9:333.","journal-title":"Cell Death Discov"},{"key":"6448_CR96","doi-asserted-by":"publisher","first-page":"8679","DOI":"10.1080\/21655979.2021.1991160","volume":"12","author":"W Yin","year":"2021","unstructured":"Yin W, Zhang K, Deng Q, et al. AZD3759 inhibits glioma through the Blockade of the epidermal growth factor receptor and Janus kinase pathways. Bioengineered. 2021;12:8679\u201389.","journal-title":"Bioengineered"},{"key":"6448_CR97","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/1061186X.2020.1745817","volume":"28","author":"S Kalimuthu","year":"2020","unstructured":"Kalimuthu S, Gangadaran P, Oh JM, et al. A new tyrosine kinase inhibitor K905-0266 inhibits proliferation and sphere formation of glioblastoma cancer cells. J Drug Target. 2020;28:933\u20138.","journal-title":"J Drug Target"},{"key":"6448_CR98","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","volume":"10","author":"J Yun","year":"2020","unstructured":"Yun J, Lee S-H, Kim S-Y, et al. Antitumor activity of Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020;10:1194\u2013209.","journal-title":"Cancer Discov"},{"key":"6448_CR99","doi-asserted-by":"publisher","first-page":"671328","DOI":"10.3389\/fphar.2021.671328","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Ge X, Pang J, et al. Restricting glutamine uptake enhances NSCLC sensitivity to Third-Generation EGFR-TKI almonertinib. Front Pharmacol. 2021;12:671328.","journal-title":"Front Pharmacol"},{"key":"6448_CR100","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78\u201384.","journal-title":"Lung Cancer"},{"key":"6448_CR101","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.lungcan.2013.02.004","volume":"80","author":"LA Berger","year":"2013","unstructured":"Berger LA, Riesenberg H, Bokemeyer C, et al. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer. 2013;80:242\u20138.","journal-title":"Lung Cancer"},{"key":"6448_CR102","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419\u201325.","journal-title":"J Clin Oncol"},{"key":"6448_CR103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11864-021-00871-y","volume":"22","author":"L Sudmeier","year":"2021","unstructured":"Sudmeier L, Tian S, Higgins KA. Multidisciplinary management of brain metastases from Non-Small cell lung cancer in the era of immunotherapy. Curr Treat Options Oncol. 2021;22:77.","journal-title":"Curr Treat Options Oncol"},{"key":"6448_CR104","doi-asserted-by":"publisher","first-page":"e23592","DOI":"10.1097\/MD.0000000000023592","volume":"99","author":"Y Yang","year":"2020","unstructured":"Yang Y, Pu Y, Dai N, et al. Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review. Med (Baltim). 2020;99:e23592.","journal-title":"Med (Baltim)"},{"key":"6448_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-012-0990-5","volume":"111","author":"F Burel-Vandenbos","year":"2013","unstructured":"Burel-Vandenbos F, Ambrosetti D, Coutts M, et al. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol. 2013;111:1\u201310.","journal-title":"J Neurooncol"},{"key":"6448_CR106","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1158\/1535-7163.MCT-04-0329","volume":"4","author":"D McKillop","year":"2005","unstructured":"McKillop D, Partridge EA, Kemp JV, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2005;4:641\u20139.","journal-title":"Mol Cancer Ther"},{"key":"6448_CR107","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/1078-0432.CCR-03-0155","volume":"10","author":"K Neville","year":"2004","unstructured":"Neville K, Parise RA, Thompson P, et al. Plasma and cerebrospinal fluid pharmacokinetics of Imatinib after administration to nonhuman primates. Clin Cancer Res. 2004;10:2525\u20139.","journal-title":"Clin Cancer Res"},{"key":"6448_CR108","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1078-0432.CCR-11-2529","volume":"18","author":"M Jamal-Hanjani","year":"2012","unstructured":"Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor\u2013Mutant Non\u2013Small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18:938\u201344.","journal-title":"Clin Cancer Res"},{"key":"6448_CR109","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10637-010-9569-1","volume":"30","author":"NA de Vries","year":"2012","unstructured":"de Vries NA, Buckle T, Zhao J, et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs. 2012;30:443\u20139.","journal-title":"Invest New Drugs"},{"key":"6448_CR110","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/JTO.0b013e318219ab87","volume":"6","author":"B Weber","year":"2011","unstructured":"Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011;6:1287\u20139.","journal-title":"J Thorac Oncol"},{"key":"6448_CR111","doi-asserted-by":"publisher","first-page":"8366","DOI":"10.18632\/oncotarget.3187","volume":"6","author":"Y-D Zeng","year":"2015","unstructured":"Zeng Y-D, Liao H, Qin T, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget. 2015;6:8366\u201376.","journal-title":"Oncotarget"},{"key":"6448_CR112","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3892\/mco.2013.190","volume":"2","author":"Y Deng","year":"2014","unstructured":"Deng Y, Feng W, Wu J, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2:116\u201320.","journal-title":"Mol Clin Oncol"},{"key":"6448_CR113","doi-asserted-by":"publisher","first-page":"45193","DOI":"10.1038\/srep45193","volume":"7","author":"Y Fan","year":"2017","unstructured":"Fan Y, Xu Y, Gong L, et al. Effects of Icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Sci Rep. 2017;7:45193.","journal-title":"Sci Rep"},{"key":"6448_CR114","doi-asserted-by":"publisher","first-page":"dju151","DOI":"10.1093\/jnci\/dju151","volume":"106","author":"SM Lee","year":"2014","unstructured":"Lee SM, Lewanski CR, Counsell N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst. 2014;106:dju151.","journal-title":"J Natl Cancer Inst"},{"key":"6448_CR115","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2147\/DDDT.S53011","volume":"7","author":"H Zhuang","year":"2013","unstructured":"Zhuang H, Yuan Z, Wang J, et al. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther. 2013;7:1179\u201386.","journal-title":"Drug Des Devel Ther"},{"key":"6448_CR116","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","volume":"25","author":"J Yun","year":"2019","unstructured":"Yun J, Hong MH, Kim S-Y, et al. YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant Non-Small cell lung cancer. Clin Cancer Res. 2019;25:2575\u201387.","journal-title":"Clin Cancer Res"},{"key":"6448_CR117","doi-asserted-by":"publisher","first-page":"175571","DOI":"10.1016\/j.ejphar.2023.175571","volume":"945","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li Y, Han Y, et al. Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor. Eur J Pharmacol. 2023;945:175571.","journal-title":"Eur J Pharmacol"},{"key":"6448_CR118","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","volume":"85","author":"A Chakravarti","year":"2013","unstructured":"Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013;85:1206\u201311.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6448_CR119","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","volume":"80","author":"JH Uhm","year":"2011","unstructured":"Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo\/North central cancer treatment group study N0074. Int J Radiat Oncol Biol Phys. 2011;80:347\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6448_CR120","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","volume":"98","author":"DM Peereboom","year":"2010","unstructured":"Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with Temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98:93\u20139.","journal-title":"J Neurooncol"},{"key":"6448_CR121","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","volume":"27","author":"MJ n den Bent","year":"2009","unstructured":"n den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus Temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27:1268\u201374.","journal-title":"J Clin Oncol"},{"key":"6448_CR122","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","volume":"21","author":"EQ Lee","year":"2015","unstructured":"Lee EQ, Kaley TJ, Duda DG, et al. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and Temozolomide with or without Vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res. 2015;21:3610\u20138.","journal-title":"Clin Cancer Res"},{"key":"6448_CR123","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-014-1631-y","volume":"121","author":"AD Norden","year":"2015","unstructured":"Norden AD, Schiff D, Ahluwalia MS, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015;121:297\u2013302.","journal-title":"J Neurooncol"},{"key":"6448_CR124","first-page":"430","volume":"17","author":"DA Reardon","year":"2015","unstructured":"Reardon DA, Nabors LB, Mason WP, et al. Phase i\/randomized phase II study of Afatinib, an irreversible erbb family blocker, with or without protracted Temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17:430\u20139.","journal-title":"Neuro Oncol"},{"key":"6448_CR125","doi-asserted-by":"publisher","first-page":"e0156369","DOI":"10.1371\/journal.pone.0156369","volume":"11","author":"N Brown","year":"2016","unstructured":"Brown N, McBain C, Nash S, et al. Multi-Center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent\/progressive glioblastoma. PLoS ONE. 2016;11:e0156369.","journal-title":"PLoS ONE"},{"key":"6448_CR126","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/annonc\/mdg153","volume":"14","author":"JL Villano","year":"2003","unstructured":"Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol. 2003;14:656\u20138.","journal-title":"Ann Oncol"},{"key":"6448_CR127","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3816\/CLC.2004.n.026","volume":"6","author":"Y Namba","year":"2004","unstructured":"Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer. 2004;6:123\u20138.","journal-title":"Clin Lung Cancer"},{"key":"6448_CR128","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0169-5002(03)00189-2","volume":"41","author":"F Cappuzzo","year":"2003","unstructured":"Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41:227\u201331.","journal-title":"Lung Cancer"},{"key":"6448_CR129","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.lungcan.2004.04.036","volume":"46","author":"K Hotta","year":"2004","unstructured":"Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib (Iressa, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer. 2004;46:255\u201361.","journal-title":"Lung Cancer"},{"key":"6448_CR130","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","volume":"15","author":"GL Ceresoli","year":"2004","unstructured":"Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15:1042\u20137.","journal-title":"Ann Oncol"},{"key":"6448_CR131","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.lungcan.2005.05.022","volume":"50","author":"MK Kim","year":"2005","unstructured":"Kim MK, Lee KH, Lee JK, et al. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer. 2005;50:265\u20139.","journal-title":"Lung Cancer"},{"key":"6448_CR132","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.lungcan.2007.03.011","volume":"57","author":"C Wu","year":"2007","unstructured":"Wu C, Li YL, Wang ZM, et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007;57:359\u201364.","journal-title":"Lung Cancer"},{"key":"6448_CR133","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1183\/09031936.00195609","volume":"37","author":"R Porta","year":"2011","unstructured":"Porta R, S\u00e1nchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37:624\u201331.","journal-title":"Eur Respir J"},{"key":"6448_CR134","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","volume":"13","author":"C Grommes","year":"2011","unstructured":"Grommes C, Oxnard GR, Kris MG, et al. Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13:1364\u20139.","journal-title":"Neuro Oncol"},{"key":"6448_CR135","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jtho.2016.11.007","volume":"12","author":"YL Wu","year":"2017","unstructured":"Wu YL, Yang J-J, Zhou C, et al. PL03.05: BRAIN: A phase III trial comparing WBI and chemotherapy with Icotinib in NSCLC with brain metastases harboring EGFR mutations (CTONG 1201). J Thorac Oncol. 2017;12:S6.","journal-title":"J Thorac Oncol"},{"key":"6448_CR136","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler M, Wu Y-L, Hirsh V, et al. First-Line Afatinib versus chemotherapy in patients with Non-Small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380\u201390.","journal-title":"J Thorac Oncol"},{"key":"6448_CR137","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","volume":"36","author":"Y-L Wu","year":"2018","unstructured":"Wu Y-L, Ahn M-J, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-Positive advanced Non-Small-Cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36:2702\u20139.","journal-title":"J Clin Oncol"},{"key":"6448_CR138","doi-asserted-by":"publisher","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(33):3290\u20133297. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118.","DOI":"10.1200\/JCO.2018.78.3118"},{"key":"6448_CR139","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated advanced Non-Small-Cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"6448_CR140","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jtho.2022.07.1143","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi Y, Chen G, Wang X, et al. Central nervous system efficacy of Furmonertinib (AST2818) versus gefitinib as First-Line treatment for EGFR-Mutated NSCLC: results from the FURLONG study. J Thorac Oncol. 2022;17:1297\u2013305.","journal-title":"J Thorac Oncol"},{"key":"6448_CR141","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1200\/JCO.2022.40.16_suppl.9096","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu S, Dong X, Jian H, et al. Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS). JCO. 2022;40:9096\u20139096.","journal-title":"JCO"},{"key":"6448_CR142","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1200\/JCO.2023.41.16_suppl.9001","volume":"41","author":"Y-L Wu","year":"2023","unstructured":"Wu Y-L, Zhou Q, Wang J, et al. Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non\u2013small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. JCO. 2023;41:9001\u20139001.","journal-title":"JCO"},{"key":"6448_CR143","doi-asserted-by":"publisher","first-page":"102238","DOI":"10.1016\/j.eclinm.2023.102238","volume":"64","author":"S-Y Maggie Liu","year":"2023","unstructured":"Maggie Liu S-Y, Dong X-R, Wang Z, et al. Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. EClinicalMedicine. 2023;64:102238.","journal-title":"EClinicalMedicine"},{"key":"6448_CR144","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","volume":"17","author":"BC Cho","year":"2022","unstructured":"Cho BC, Han J-Y, Kim S-W, et al. A phase 1\/2 study of lazertinib 240\u00a0mg in patients with advanced EGFR T790M-Positive NSCLC after previous EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2022;17:558\u201367.","journal-title":"J Thorac Oncol"},{"key":"6448_CR145","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00109-019-01843-4","volume":"97","author":"C Ye","year":"2019","unstructured":"Ye C, Pan B, Xu H, et al. Co-delivery of GOLPH3 SiRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma. J Mol Med (Berl). 2019;97:1575\u201388.","journal-title":"J Mol Med (Berl)"},{"key":"6448_CR146","doi-asserted-by":"publisher","first-page":"10926","DOI":"10.1039\/D1FO01611C","volume":"12","author":"A Bagherian","year":"2021","unstructured":"Bagherian A, Roudi B, Masoudian N, et al. Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib. Food Funct. 2021;12:10926\u201337.","journal-title":"Food Funct"},{"key":"6448_CR147","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.7150\/thno.42234","volume":"10","author":"W Yin","year":"2020","unstructured":"Yin W, Zhao Y, Kang X, et al. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation. Theranostics. 2020;10:6122\u201335.","journal-title":"Theranostics"},{"key":"6448_CR148","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/1878-0261.12394","volume":"12","author":"DH Kim","year":"2018","unstructured":"Kim DH, Choi YJ, Sung KJ, et al. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer. Mol Oncol. 2018;12:2182\u201390.","journal-title":"Mol Oncol"},{"key":"6448_CR149","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.31557\/APJCP.2021.22.12.3993","volume":"22","author":"R Amini","year":"2021","unstructured":"Amini R, Karami H, Bayat M. Combination therapy with PIK3R3-siRNA and EGFR-TKI erlotinib synergistically suppresses glioblastoma cell growth in vitro. Asian Pac J Cancer Prev. 2021;22:3993\u20134000.","journal-title":"Asian Pac J Cancer Prev"},{"key":"6448_CR150","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12964-023-01400-0","volume":"21","author":"T Guo","year":"2023","unstructured":"Guo T, Wu C, Zhang J, et al. Dual Blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma. Cell Commun Signal. 2023;21:363.","journal-title":"Cell Commun Signal"},{"key":"6448_CR151","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12967-016-0803-2","volume":"14","author":"T Shingu","year":"2016","unstructured":"Shingu T, Holmes L, Henry V, et al. Suppression of RAF\/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med. 2016;14:46.","journal-title":"J Transl Med"},{"key":"6448_CR152","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10637-018-0575-z","volume":"36","author":"S Liu","year":"2018","unstructured":"Liu S, Tang Y, Yuan X, et al. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of Palbociclib and erlotinib in glioblastoma cells. Invest New Drugs. 2018;36:961\u20139.","journal-title":"Invest New Drugs"},{"key":"6448_CR153","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/neuonc\/nos266","volume":"14","author":"S Eimer","year":"2012","unstructured":"Eimer S, Dugay F, Airiau K, et al. Cyclopamine cooperates with EGFR Inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro Oncol. 2012;14:1441\u201351.","journal-title":"Neuro Oncol"},{"key":"6448_CR154","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.molonc.2012.09.004","volume":"6","author":"A Nebbioso","year":"2012","unstructured":"Nebbioso A, Carafa V, Benedetti R, et al. Trials with epigenetic drugs: an update. Mol Oncol. 2012;6:657\u201382.","journal-title":"Mol Oncol"},{"key":"6448_CR155","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/nm.4415","volume":"23","author":"X Jin","year":"2017","unstructured":"Jin X, Kim LJY, Wu Q, et al. Targeting glioma stem cells through combined BMI1 and EZH2 Inhibition. Nat Med. 2017;23:1352\u201361.","journal-title":"Nat Med"},{"key":"6448_CR156","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4161\/epi.25440","volume":"8","author":"J Clarke","year":"2013","unstructured":"Clarke J, Penas C, Pastori C, et al. Epigenetic pathways and glioblastoma treatment. Epigenetics. 2013;8:785\u201395.","journal-title":"Epigenetics"},{"key":"6448_CR157","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.gde.2017.03.015","volume":"42","author":"AD Kelly","year":"2017","unstructured":"Kelly AD, Issa J-PJ. The promise of epigenetic therapy: reprogramming the cancer epigenome. Curr Opin Genet Dev. 2017;42:68\u201377.","journal-title":"Curr Opin Genet Dev"},{"key":"6448_CR158","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12031-019-01280-5","volume":"68","author":"M Buendia Duque","year":"2019","unstructured":"Buendia Duque M, Pinheiro K, de V, Thomaz A, et al. Combined Inhibition of HDAC and EGFR reduces viability and proliferation and enhances STAT3 mRNA expression in glioblastoma cells. J Mol Neurosci. 2019;68:49\u201357.","journal-title":"J Mol Neurosci"},{"key":"6448_CR159","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1124\/jpet.109.155705","volume":"331","author":"EP Jane","year":"2009","unstructured":"Jane EP, Premkumar DR, Addo-Yobo SO, et al. Abrogation of mitogen-activated protein kinase and Akt signaling by Vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. J Pharmacol Exp Ther. 2009;331:327\u201337.","journal-title":"J Pharmacol Exp Ther"},{"key":"6448_CR160","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2011.06.141","volume":"411","author":"A-M Marino","year":"2011","unstructured":"Marino A-M, Sofiadis A, Baryawno N, et al. Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models. Biochem Biophys Res Commun. 2011;411:208\u201312.","journal-title":"Biochem Biophys Res Commun"},{"key":"6448_CR161","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11523-015-0372-y","volume":"11","author":"K Liffers","year":"2016","unstructured":"Liffers K, Kolbe K, Westphal M, et al. Histone deacetylase inhibitors resensitize EGFR\/EGFRvIII-Overexpressing, Erlotinib-Resistant glioblastoma cells to tyrosine kinase Inhibition. Target Oncol. 2016;11:29\u201340.","journal-title":"Target Oncol"},{"issue":"12","key":"6448_CR162","doi-asserted-by":"publisher","first-page":"e7362","DOI":"10.1002\/cam4.7362","volume":"13","author":"FM Ippen","year":"2024","unstructured":"Ippen FM, Scherm A, Kessler T, et al. Targeted agents in patients with progressive glioblastoma-A systematic meta-analysis of randomized clinical trials. Cancer Med. 2024;13(12):e7362.","journal-title":"Cancer Med"},{"issue":"9","key":"6448_CR163","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/vaccines11091460","volume":"11","author":"F Li","year":"2023","unstructured":"Li F, Wu H, Du X, et al. Epidermal growth factor Receptor-Targeted neoantigen peptide vaccination for the treatment of Non-Small cell lung cancer and glioblastoma. Vaccines (Basel). 2023;11(9):1460.","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"6448_CR164","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD, et al. Rindopepimut with Temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373\u201385.","journal-title":"Lancet Oncol"},{"issue":"2","key":"6448_CR165","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/cns.14.54","volume":"4","author":"A Hdeib","year":"2015","unstructured":"Hdeib A, Sloan AE. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax\u00ae platform in the treatment of glioblastoma multiforme. CNS Oncol. 2015;4(2):63\u20139.","journal-title":"CNS Oncol"},{"issue":"9","key":"6448_CR166","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3109\/1061186X.2015.1025077","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Hao Y, Li H, et al. Co-delivery of doxorubicin and SiRNA for glioma therapy by a brain targeting system: angiopep-2-modified Poly (lactic-co-glycolic acid) nanoparticles. J Drug Target. 2015;23(9):832\u201346.","journal-title":"J Drug Target"},{"issue":"Suppl 2","key":"6448_CR167","first-page":"A1","volume":"12","author":"NM Orozco","year":"2024","unstructured":"Orozco NM, Nechanitzky R, Snelling S, et al. J Immunother Cancer. 2024;12(Suppl 2):A1\u20131683.","journal-title":"J Immunother Cancer"},{"key":"6448_CR168","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10\u20139.","journal-title":"Ann Oncol"},{"key":"6448_CR169","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.","journal-title":"Sci Transl Med"},{"issue":"4","key":"6448_CR170","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3892\/ol.2022.13476","volume":"24","author":"S Yuan","year":"2022","unstructured":"Yuan S, Chen W, Yang J, et al. Tumor-associated macrophage-derived exosomes promote EGFR-TKI resistance in non-small cell lung cancer by regulating the AKT, ERK1\/2 and STAT3 signaling pathways. Oncol Lett. 2022;24(4):356.","journal-title":"Oncol Lett"},{"key":"6448_CR171","doi-asserted-by":"publisher","first-page":"1209947","DOI":"10.3389\/fimmu.2023.1209947","volume":"14","author":"D Cheng","year":"2023","unstructured":"Cheng D, Ge K, Yao X, et al. Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects. Front Immunol. 2023;14:1209947.","journal-title":"Front Immunol"},{"issue":"1","key":"6448_CR172","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/0118715206261966231103043418","volume":"24","author":"X Tang","year":"2024","unstructured":"Tang X, Chen Y, Jiao D, et al. Tumor-associated macrophages mediate gefitinib resistance in lung cancer through HGF\/c-met signaling pathway. Anticancer Agents Med Chem. 2024;24(1):30\u20138.","journal-title":"Anticancer Agents Med Chem"},{"key":"6448_CR173","doi-asserted-by":"publisher","first-page":"822085","DOI":"10.3389\/fonc.2022.822085","volume":"12","author":"X Liu","year":"2022","unstructured":"Liu X, Liu Y, Qi Y, et al. Signal pathways involved in the interaction between Tumor-Associated macrophages\/tams and glioblastoma cells. Front Oncol. 2022;12:822085.","journal-title":"Front Oncol"},{"issue":"12","key":"6448_CR174","doi-asserted-by":"publisher","first-page":"11701","DOI":"10.1007\/s13277-014-2660-z","volume":"35","author":"J Cui","year":"2014","unstructured":"Cui J, Hu YF, Feng XM, et al. EGFR inhibitors and autophagy in cancer treatment. Tumour Biol. 2014;35(12):11701\u20139.","journal-title":"Tumour Biol"},{"issue":"7","key":"6448_CR175","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/138920010792927316","volume":"11","author":"XK Wang","year":"2010","unstructured":"Wang XK, Fu LW. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. Curr Drug Metab. 2010;11(7):618\u201328.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"6448_CR176","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","volume":"2","author":"W L\u00f6scher","year":"2005","unstructured":"L\u00f6scher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86\u201398.","journal-title":"NeuroRx"},{"issue":"7","key":"6448_CR177","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2174\/1871520616666151120121928","volume":"16","author":"AL Iorio","year":"2016","unstructured":"Iorio AL, Ros Md, Fantappi\u00e8 O, et al. Blood-Brain barrier and breast cancer resistance protein: A limit to the therapy of CNS tumors and neurodegenerative diseases. Anticancer Agents Med Chem. 2016;16(7):810\u20135.","journal-title":"Anticancer Agents Med Chem"},{"key":"6448_CR178","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039\u201343.","journal-title":"Science"},{"key":"6448_CR179","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","volume":"34","author":"GR Oxnard","year":"2016","unstructured":"Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced Non-Small-Cell lung cancer. J Clin Oncol. 2016;34:3375\u201382.","journal-title":"J Clin Oncol"},{"key":"6448_CR180","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1016\/j.ejca.2011.06.046","volume":"47","author":"A Becker","year":"2011","unstructured":"Becker A, Crombag L, Heideman DaM, et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer. 2011;47:2603\u20136.","journal-title":"Eur J Cancer"},{"key":"6448_CR181","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fonc.2014.00238","volume":"4","author":"B Melosky","year":"2014","unstructured":"Melosky B, Hirsh V. Management of common toxicities in metastatic NSCLC related to Anti-Lung cancer therapies with EGFR-TKIs. Front Oncol. 2014;4:238.","journal-title":"Front Oncol"},{"key":"6448_CR182","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803\u201312.","journal-title":"Nat Rev Cancer"},{"key":"6448_CR183","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351\u20137.","journal-title":"J Clin Oncol"},{"key":"6448_CR184","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3747\/co.v18i3.877","volume":"18","author":"V Hirsh","year":"2011","unstructured":"Hirsh V. Managing treatment-related adverse events associated with Egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011;18:126\u201338.","journal-title":"Curr Oncol"},{"key":"6448_CR185","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/era.13.31","volume":"13","author":"JC-H Yang","year":"2013","unstructured":"Yang JC-H, Reguart N, Barinoff J, et al. Diarrhea associated with Afatinib: an oral erbb family blocker. Expert Rev Anticancer Ther. 2013;13:729\u201336.","journal-title":"Expert Rev Anticancer Ther"},{"key":"6448_CR186","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392.","journal-title":"N Engl J Med"},{"key":"6448_CR187","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, et al. Detection of Circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.","journal-title":"Sci Transl Med"},{"key":"6448_CR188","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature25169","volume":"553","author":"SC Mack","year":"2018","unstructured":"Mack SC, Pajtler KW, Chavez L, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018;553:101\u20135.","journal-title":"Nature"},{"key":"6448_CR189","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with Tumor-Treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: A randomized clinical trial. JAMA. 2015;314:2535\u201343.","journal-title":"JAMA"},{"key":"6448_CR190","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41698-019-0078-1","volume":"3","author":"F Azuaje","year":"2019","unstructured":"Azuaje F. Artificial intelligence for precision oncology: beyond patient stratification. NPJ Precis Oncol. 2019;3:6.","journal-title":"NPJ Precis Oncol"},{"key":"6448_CR191","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1634\/theoncologist.2017-0572","volume":"23","author":"MS Ahluwalia","year":"2018","unstructured":"Ahluwalia MS, Becker K, Levy BP. Epidermal growth factor receptor tyrosine kinase inhibitors for central nervous system metastases from Non-Small cell lung cancer. Oncologist. 2018;23:1199\u2013209.","journal-title":"Oncologist"},{"key":"6448_CR192","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biomaterials.2016.06.051","volume":"103","author":"J Aparicio-Blanco","year":"2016","unstructured":"Aparicio-Blanco J, Mart\u00edn-Sabroso C, Torres-Su\u00e1rez. A-I: in vitro screening of nanomedicines through the blood brain barrier: A critical review. Biomaterials. 2016;103:229\u201355.","journal-title":"Biomaterials"},{"key":"6448_CR193","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1023\/A:1020291229317","volume":"60","author":"RA Patchell","year":"2002","unstructured":"Patchell RA, Regine WF, Ashton P, et al. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2002;60:37\u201342.","journal-title":"J Neurooncol"},{"key":"6448_CR194","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41598-018-36340-0","volume":"9","author":"T Mainprize","year":"2019","unstructured":"Mainprize T, Lipsman N, Huang Y, et al. Blood-Brain barrier opening in primary brain tumors with Non-invasive MR-Guided focused ultrasound: A clinical safety and feasibility study. Sci Rep. 2019;9:321.","journal-title":"Sci Rep"},{"key":"6448_CR195","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20:810\u20137.","journal-title":"Cancer Cell"},{"key":"6448_CR196","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5:1164\u201377.","journal-title":"Cancer Discov"},{"key":"6448_CR197","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/path.4583","volume":"237","author":"JM Saunus","year":"2015","unstructured":"Saunus JM, Quinn MCJ, Patch A-M, et al. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol. 2015;237:363\u201378.","journal-title":"J Pathol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06448-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:01:21Z","timestamp":1744822881000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06448-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":197,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6448"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06448-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}